TP53INP1 suppresses gemcitabine resistance in pancreatic cancer, sorafenib resistance and DDP resistance in liver cancer, paclitaxel resistance in breast cancer, DDP resistance in lung cancer, etc. [39–42]. Here, TP53INP1 is linked to lung cancer.